Merck signs up to $3.3 billion cancer drug deal with LaNova
16 Nov 2024 //
REUTERS
Merck Licenses LM-299, Anti-PD-1/VEGF Bispecific Antibody
14 Nov 2024 //
BUSINESSWIRE
LaNova Initiates Phase 1 Trial Of Bispecific Antibody LM-299
18 Oct 2024 //
PR NEWSWIRE
AstraZeneca enters potential $600M licensing deal with Chinese startup
16 May 2023 //
ENDPTS
LaNova enters exclusive license agreement with AstraZeneca for LM-305
15 May 2023 //
PHARMABIZ
LaNova Medicines Announces Global Exclusive License Agreement with AZ for LM-305
12 May 2023 //
PR NEWSWIRE